Mitochondria as targets for established and novel anti-cancer agents

Drug Resistance Updates

Volumn 4, Issue 2, 2001, Pages 85-91

  Grad, Jennifer M ^a   Cepero, Enrique ^a   Boise, Lawrence H ^a  

^a UNIVERSITY OF MIAMI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 METHOXYESTRADIOL; 6 [3 (1 ADAMANTYL) 4 HYDROXYPHENYL] 2 NAPHTHOIC ACID; ANTINEOPLASTIC AGENT; BENZODIAZEPINE RECEPTOR; BONGKREKIC ACID; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; LONIDAMINE; MELPHALAN; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; NAVELBINE; PACLITAXEL; TRANSCRIPTION FACTOR;

ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CLINICAL TRIAL; DNA DAMAGE; DRUG MECHANISM; DRUG POTENTIATION; DRUG RECEPTOR BINDING; DRUG TARGETING; HUMAN; MITOCHONDRION; PRIORITY JOURNAL; SHORT SURVEY; TUMOR CELL;

EID: 0034937266     PISSN: 13687646     EISSN: None     Source Type: Journal    
DOI: 10.1054/drup.2001.0192     Document Type: Short Survey

References (69)

1. Clinical multidrug resistance in cancer: A multifactorial problem
2. Dysregulation of apoptosis in cancer
3. Cell-free apoptosis in Xenopus egg extracts: Inhibition by Bcl-2 and requirement for an organelle fraction enriched in mitochondria
4. Induction of apoptotic program in cell-free extracts: Requirement for dATP and cytochrome c
5. Bcl-2 proteins: Regulators of cell apoptosis or of mitochondrial homeostasis
6. Bcl-2 family members and the mitochondria in apoptosis
7. A caspase-activated DNase that degrades DNA during apoptosis, and its inhibitor ICAD
8. DFF, a heterodimeric protein that functions downstream of caspase-3 to trigger DNA fragmentation during apoptosis
9. Caspase-3-generated fragment of gelsolin: Effector of morphological change in apoptosis
10. Cleavage of focal adhesion kinase by caspases during apoptosis
11. Membrane and morphological changes in apoptotic cells regulated by caspase-mediated activation of PAK2
12. L inhibits cytochrome c release but not mitochondrial depolarization during the activation of multiple death pathways by tumor necrosis factor-alpha
13. The coordinate release of cytochrome c during apoptosis is rapid, complete and kinetically invariant
14. Mitochondria and apoptosis
15. 3H] diazepam binding
16. Subcellular localization of "peripheral-type" benzodiazapine binding sites in rat brain
17. Peripheral-type benzodiazapine receptors: Autoradiographic localization in whole-body sections of neonatal rats
18. The Peripheral-type benzodiazapine receptor: Localization to the mitochondrial outer membrane
19. Increased expression of diazepam binding inhibitor in human brain tumors
20. Up-regulation of peripheral benzodiazapine receptors system in hepatocellular carcinoma
21. Expression of Peripheral-type benzodiazapine receptor and diazepam binding inhibitor in human astrocytomas: Relationship to proliferation
22. The peripheral benzodiazepine receptors: A review
23. The mitochondrial permeability transition pore
24. Bax directly induces release of cytochrome c from isolated mitochondria
25. Bax interacts with the permeability transition pore to induce permeability transition and cytochrome c release in isolated mitochondria
26. Bax and adenine nucleotide translocator cooperate in mitochondrial control of apoptosis
27. 2+ ions
28. PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2 mediated cytoprotection
29. Monitoring by PET of macrophage accumulation in brain after ischemic stroke
30. Imaging microglial activation in vivo
31. 11C](R)-PK11195 to image focal and regional brain pathology
32. 11C](R)-PK11195 positron emission tomography imaging of activated microglia in vivo in Rasmussen's encephalitis
33. Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore
34. Treatment of melanoma cells with the synthetic retinoid CD437 induces apoptotsis via activation of AP-1 in vitro and causes growth inhibition in xenografts in vivo
35. Mechanisms of apoptosis induced by the synthetic retinoid CD437 in human non small cell lung carcinoma cells
36. L expression and its downregulation by a novel retinoid in breast carcinoma cells
37. Retinoid induced apoptosis in leukemia cells through a retinoic acid nuclear receptor independent pathway
38. The novel retinoid 6-[3-(l-admantyl)-4-hydroxyphenyl]-2-naphtalene carboxylic acid can trigger apoptosis through a mitochondrial pathway independent of the nucleus
39. Requirement for the orphan steroid receptor Nur77 in apoptosis of T-cell hybridomas
40. Apoptotic signals delivered through the T-cell receptor of a T-cell hybrid require the immediate-early gene nur77
41. Molecular determinants of AHPN (CD437)-induced growth arrest and apoptosis in human lung cancer cell lines
42. Antisense TR3 orphan receptor can increase prostate cancer cell viability with etoposide treatment
43. Identification of a new member of the steroid receptor super-family by cloning and sequence analysis
44. A gene inducible by serum growth factors encodes a member of the steroid and thyroid hormone receptor superfamily
45. Molecular mechanisms of action of steroid/thyroid receptor superfamily members
46. Structure, mapping and expression of a growth factor inducible gene encoding a putative nuclear hormonal binding receptor
47. Apoptosis of nur77/N10-transgenic thymocytes involves the Fas/Fas ligand pathway
48. Functional redundancy of the Nur77 and Nor-1 orphan steroid receptors in T-cell apoptosis
49. Cytochrome c release and apoptosis induced by mitochondrial targeting of nuclear orphan receptor TR3
50. Cyclosporin A blocks apoptosis by inhibiting the DNA binding activity of the transcription factor Nur77
51. Modulation of retinoid signalling through NGF-induced nuclear export of NGFI-B
52. Apoptosis and the maintenance of homeostasis in the immune system
53. Superinduction of wild type p53 protein after 2-methoxyestradiol treatment of Ad5p53-transduced cells induces tumor cell apoptosis
54. Superoxide dismutase as a target for the selective killing of cancer cells
55. Synthesis antitubulin and antimitotic activity, and cytotoxicity of analogs of 2-methoxyestradiol, an endogenous mammalian metabolite of estradiol that inhibits tubulin polymerization by binding to the colchicine binding site
56. The endogenous estrogen metabolite 2-methoxyestradiol inhibits angiogenesis and supresses tumor growth
57. Efficacy of lonidamine combined with different DNA-damaging agents in the treatment of the MX-1 tumor xenograft
58. Modulating effect of lonidamine on response to doxorubicin in metastatic breast cancer patients: Results from a multicenter prospective randomized trial
59. Cisplatin, epirubucin, and lonidamine combination regimen as first line chemotherapy for metastatic breast cancer: A pilot study
60. Cisplatin, epirubicin, and vindesine with or without lonidamine in the treatment of inoperable nonsmall cell lung carcinoma: A multicenter randomized clinical trial
61. Lonidamine triggers apoptosis via a direct, Bcl-2 inhibited effect on the mitochondrial permeability transition pore
62. Bcl-2 inhibits mitochondrial metabolism and lonidamine-induced apoptosis in adriamycin-resistant MCF7 cells
63. Tumor cell resistance to DNA topoisomerase II inhibitors: New developments
64. Distinct pathways for stimulation of cytochrome c release by etoposide
65. The taxoids. Comparative clinical pharmacology and therapeutic potential
66. Molecular mechanisms of resistance to taxanes and therapeutic implications
67. Deletion of the loop region of Bcl-2 completely blocks paclitaxel-induced apoptosis
68. Paclitaxel induces release of cytochrome c from mitochondria isolated from human neuroblastoma cells
69. Mechanism of mitotic block and inhibition of cell proliferation by Taxol at low concentrations